Susquehanna International Group, LLP Checkpoint Therapeutics, Inc. Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.02 - $10.6 $3,670 - $38,149	-3,599 Reduced 21.61%	13,053 $14,000
Q2 2022 Aug 15, 2022	SELL	$0.97 - $1.77 $133,594 - $243,775	-137,726 Reduced 89.21%	16,652 $17,000
Q1 2022 May 16, 2022	SELL	$1.53 - $3.25 $1.06 Million - $2.24 Million	-689,621 Reduced 81.71%	154,378 $273,000
Q4 2021 Feb 14, 2022	BUY	$2.68 - $4.46 $1.29 Million - $2.14 Million	479,648 Added 131.64%	843,999 $2.63 Million
Q3 2021 Nov 15, 2021	BUY	$2.5 - $3.53 $342,672 - $483,853	137,069 Added 60.31%	364,351 $1.2 Million
Q2 2021 Aug 11, 2021	BUY	$2.36 - $3.2 $536,385 - $727,302	227,282 New	227,282 $670,000
Q1 2021 May 17, 2021	SELL	$2.6 - $4.16 $26,046 - $41,674	-10,018 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$2.19 - $2.96 $21,939 - $29,653	10,018 New	10,018 $27,000
Q2 2020 Aug 14, 2020	SELL	$1.19 - $2.27 $23,732 - $45,270	-19,943 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$1.11 - $2.43 $22,136 - $48,461	19,943 New	19,943 $30,000
Q4 2019 Feb 14, 2020	SELL	$1.18 - $2.39 $19,864 - $40,233	-16,834 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$2.15 - $3.36 $31,645 - $49,455	-14,719 Reduced 46.65%	16,834 $42,000
Q2 2019 Aug 16, 2019	BUY	$2.75 - $5.0 $4,713 - $8,570	1,714 Added 5.74%	31,553 $96,000
Q2 2019 Aug 14, 2019	BUY	$2.75 - $5.0 $82,057 - $149,195	29,839 New	29,839 $90,000
Q1 2019 May 15, 2019	SELL	$2.01 - $4.01 $26,588 - $53,044	-13,228 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$1.54 - $3.35 $20,371 - $44,313	13,228 New	13,228 $24,000
Q3 2018 Nov 14, 2018	SELL	$2.46 - $4.72 $31,960 - $61,322	-12,992 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$2.45 - $4.39 $31,830 - $57,034	12,992 New	12,992 $39,000

Others Institutions Holding CKPT

# of Institutions

Shares Held

1.91M

Call Options Held

Put Options Held

View Full List

About Checkpoint Therapeutics, Inc.

Ticker CKPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,497,000
Market Cap $299M
Description
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to...

More about CKPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account